Bayesian Designs for Phase I–II Clinical Trials
Latest Publications

TOTAL DOCUMENTS

14
(FIVE YEARS 0)

H-INDEX

0
(FIVE YEARS 0)

Published By Chapman And Hall/CRC

9781315371405
Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Why Conduct Phase I–II Trials?

2017 ◽  
pp. 1-28
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall
Keyword(s):  
Phase I

The Phase I–II Paradigm

2017 ◽  
pp. 29-42
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall
Keyword(s):  
Phase I

Establishing Priors

2017 ◽  
pp. 43-57
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall

Optimizing Sedative Dose in Preterm Infants

2017 ◽  
pp. 267-282
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall
Keyword(s):  
Preterm Infants ◽  
Sedative Dose

Efficacy–Toxicity Trade-Off-Based Designs

2017 ◽  
pp. 59-87
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall
Keyword(s):  
Trade Off

Combination Trials

2017 ◽  
pp. 149-178
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall

Designs with Late-Onset Outcomes

2017 ◽  
pp. 89-104
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall
Keyword(s):  
Late Onset

Optimizing Doses in Two Cycles

2017 ◽  
pp. 203-222
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall

Optimizing Dose and Schedule

2017 ◽  
pp. 223-244
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall

Optimizing Molecularly Targeted Agents

2017 ◽  
pp. 179-202
Author(s):  
Ying Yuan ◽  
Hoang Q. Nguyen ◽  
Peter F. Thall
Keyword(s):  
Targeted Agents ◽  
Molecularly Targeted Agents
Load More ...
Sign in / Sign up

Export Citation Format

Share Document